The invention provides an isolated chimeric virus comprising bocavirus capsid protein, e.g., an isolated chimeric virus comprising human bocavirus capsid protein, and a recombinant adeno-associated viral (AAV) genome, an isolated recombinant bocavirus (rBoV) comprising human bocavirus capsid protein and a recombinant Boy genome, and uses therefor, for example, in gene therapy for diseases in a mammal including diseases with aberrant expression of an endogenous gene product.

The invention provides an isolated chimeric virus comprising bocavirus capsid protein, e.g., an isolated chimeric virus comprising human bocavirus capsid protein, and a recombinant adeno-associated viral (AAV) genome, an isolated recombinant bocavirus (rBoV) comprising human bocavirus capsid protein and a recombinant Boy genome, and uses therefor, for example, in gene therapy for diseases in a mammal including diseases with aberrant expression of an endogenous gene product.

The present invention relates to parvovirus mutated structural proteins comprising insertions of mimotopes of a HER2, compositions, multimeric structures, medicaments and vaccines comprising the same, nucleic acids, expression cassettes, constructs, vectors and cells comprising the nucleic acids, methods of preparing the structural proteins and methods of inducing a B-cell response or of treating a HER2-related disease.

The invention provides a process for generating parvovirus VP1/VP2 virus like particles (VLPs). The invention further provides methods for purification of the parvovirus VLPs and immunogenic compositions that contain the VLPs. The invention also includes recombinant nucleic acid molecules that encode parvovirus VP1 and VP2, and host cells that contain the recombinant nucleic acids.

The invention provides a process for generating parvovirus VP1/VP2 virus like particles (VLPs). The invention further provides methods for purification of the parvovirus VLPs and immunogenic compositions that contain the VLPs. The invention also includes recombinant nucleic acid molecules that encode parvovirus VP1 and VP2, and host cells that contain the recombinant nucleic acids.

The present invention provides a recombinant expression vector comprising a gene encoding canine parvovirus 2a VP2 or 2b VP2 protein, a recombinant plant into which the vector is transformed, a vaccine composition against canine parvovirus, comprising canine parvovirus 2a VP2 or 2b VP2 protein obtained from the recombinant plant, and a composition for diagnosing canine parvovirus. When the recombinant plant of the present invention is used, canine parvovirus 2a VP2 or 2b VP2 antigen protein can be rapidly produced with high efficiency. Since the composition for diagnosing canine parvovirus according to the present invention uses a recombinant antigen protein, there is no possibility of contamination due to live virus handling, and thus the composition is safe, and the presence or absence of canine parvovirus infection can be rapidly diagnosed from a large amount of samples.

The present invention provides a recombinant expression vector comprising a gene encoding canine parvovirus 2a VP2 or 2b VP2 protein, a recombinant plant into which the vector is transformed, a vaccine composition against canine parvovirus, comprising canine parvovirus 2a VP2 or 2b VP2 protein obtained from the recombinant plant, and a composition for diagnosing canine parvovirus. When the recombinant plant of the present invention is used, canine parvovirus 2a VP2 or 2b VP2 antigen protein can be rapidly produced with high efficiency. Since the composition for diagnosing canine parvovirus according to the present invention uses a recombinant antigen protein, there is no possibility of contamination due to live virus handling, and thus the composition is safe, and the presence or absence of canine parvovirus infection can be rapidly diagnosed from a large amount of samples.

Vectors having a nucleotide sequence having SEQ ID NO:1 or a nucleotide sequence having at least 85% identity to SEQ ID NO:1, or a portion thereof, that is capable of regulating bocaparvovirus replication, or vectors having the complement of the nucleotide sequence, and methods of using the vectors, are provided.

Vectors having a nucleotide sequence having SEQ ID NO:1 or a nucleotide sequence having at least 85% identity to SEQ ID NO:1, or a portion thereof, that is capable of regulating bocaparvovirus replication, or vectors having the complement of the nucleotide sequence, and methods of using the vectors, are provided.

The present invention relates to a porcine parvovirus and porcine reproductive and respiratory syndrome virus vaccine for protecting a subject, preferably swine, against diseases associated with porcine parvovirus and porcine reproductive and respiratory syndrome virus. The present invention further relates to methods of producing immunogenic compositions as well as such immunogenic compositions exhibiting reduced virucidal activity.